Dr. Steven Powell
Chief Executive Officer
Steven graduated in microbiology from the University of Wales and was awarded a PhD from the University of Aberdeen. He has over 30 years operational and investment experience in pharmaceutical and healthcare R&D and his operational experience includes appointments with Beecham Pharmaceuticals (GSK), Whatman, Chiroscience, Celsis, Active Biotech, KS Biomedix and Plethora Solutions. During this time he has held four CEO roles, two in public companies.
In 2003, he joined Gilde Healthcare, a pan-European life sciences investment fund and remains an adviser to the fund. To date, Steven has co-founded 4 companies of which 2 have been sold and has invested in multiple biotechnology companies. In 2011, Steven established a successful interim management practice focused on healthcare and technology companies.
Chief Financial Officer
A chartered accountant, Nick has served as Finance Director, Deputy Chairman and Chairman on a number of Boards. Nick has over thirty years experience across a wide range of industry sectors and a track record for addressing the fundamentals in these companies and setting them up for sustainable growth. Nick has previously worked closely with Dr. Nick Kerton at Sirigen Group and Maybridge.
Mike has 25 years global Health and Pharma industry experience. He is currently Executive Chairman of iPlato an m-Health provider with 9M patient connections in the UK, Chairman of Haem02, a biotechnology company developing artificial human haemoglobin, and Chairman of Glyconics Ltd, developing diagnostics for COPD, as well as being director of Mikale Ltd. Mr Lewis is also a lecturer, speaker and invited Chair of innovation sessions at NHS Expo, Chairs the KTN Medtech group, and was past Chair of the Assisted Living Innovation platform. He previously has held senior roles at Gambro (Brussels), Boston Scientific (Paris), C.R. Bard (New Jersey), Sybron (Switzerland) and Becton Dickinson (UK).
Dr. Nicholas Kerton
Nick is an experienced director of public and private companies in the healthcare industry. Having completed a Ph.D. in Organic Synthetic Chemistry at Nottingham University, he progressed through the Wellcome Foundation, and then joined DuPont and Whatman Reeve Angel plc in senior business development and sales roles before moving into microbiology as Managing Director of Malthus Instruments, a subsidiary of Radiometer of Denmark. Nick was a member of the management team who established Celsis PLC, one of the first biotechnology companies to float on the London Stock Exchange, led the successful sale of Maybridge to Fisher Scientific International, founded Lab21 (a molecular diagnostics service funded by Merlin Biosciences) during which time he acquired three companies, and managed the Sirigen Group from initial venture capital funding in 2008 through to selling the business to Becton Dickinson in August 2012.
Dr. Andrew Blackwell
Following an MA and a PhD in psychology from the University of St Andrews, Dr Blackwell undertook postdoctoral training in cognitive neuropsychology and psychopharmacology at the University of Cambridge, working closely with the main inventors of CANTAB, Professors Trevor Robbins and Barbara Sahakian. Dr Blackwell has published numerous papers in quality journals, including Science, American Journal of Psychiatry and Neuropsychopharmacology. He joined Cambridge Cognition in 2006 and was appointed as a director and Chief Scientific Officer in 2007. Dr Blackwell became a Non-Executive Director in July 2015.
Eric brings significant experience in board-level positions to the Company, including having been Chief Financial Officer of KBC Advanced Technologies plc, Antisoma plc, Morse plc and Stanmore Implants Worldwide Holdings Limited.